广泛淋巴血管侵犯与常规淋巴血管侵犯相比,在根治性治疗的乳腺癌患者中与更高的局部区域复发风险相关
该回顾性研究纳入2009年12月至2021年8月间8837例接受根治性治疗的早期乳腺癌患者,按淋巴血管侵犯(LVI)程度分为阴性、局灶或可疑、常规(非广泛)和广泛LVI四组。广泛LVI组5年和10年局部区域复发(LRR)累积发生率分别为9.6%和13%,显著高于常规LVI组的6.8%和10%。多因素分析显示广泛LVI较非广泛LVI的LRR风险比为1.62(95%CI 1.15-2.27,P=0.005)。作者认为广泛LVI患者LRR风险更高,对于区域淋巴结照射或乳房切除术后放疗的临界候选者,广泛LVI的发现可能支持强化治疗。
要点
- 广泛LVI组5年LRR累积发生率为9.6%,10年为13%,均高于常规LVI组的6.8%和10%。
- 多因素分析中广泛LVI较非广泛LVI的LRR风险比为1.62(95%CI 1.15-2.27,P=0.005)。
- 倾向评分匹配分析中广泛LVI的LRR风险比为1.47(95%CI 1.02-2.14,P=0.041)。
核心结论
- 作者认为广泛LVI患者较常规LVI患者具有更高的LRR风险。
- 作者认为对于区域淋巴结照射或乳房切除术后放疗的临界候选者,广泛LVI的发现可能对支持强化治疗起决定性作用。
研究设计与样本
- 回顾性分析2009年12月至2021年8月间8837例接受根治性治疗的早期乳腺癌患者,临床病理资料通过回顾性复习病历摘录,LVI描述摘自病理报告。
- 按LVI程度分为阴性(5584例)、局灶或可疑LVI(461例)、常规(非广泛)LVI(2315例)和广泛LVI(477例)四组,比较复发和生存结局。
- 另进行2:1倾向评分匹配分析比较常规LVI与广泛LVI患者的结局。
主要发现
- 广泛LVI组5年和10年LRR累积发生率分别为9.6%(95%CI 7.1-13)和13%(95%CI 10-17),常规LVI组分别为6.8%(95%CI 5.7-7.9)和10%(95%CI 8.8-12)。
- 单因素分析中广泛LVI较非广泛LVI的LRR风险比为1.4(95%CI 1.03-1.89,P=0.029)。
- 多因素分析中广泛LVI较非广泛LVI的LRR风险比为1.62(95%CI 1.15-2.27,P=0.005)。
- 2:1倾向评分匹配分析中广泛LVI的LRR风险比为1.47(95%CI 1.02-2.14,P=0.041)。
- 广泛LVI组较其他组具有更差的风险特征。
临床怎么用
- 作者认为对于区域淋巴结照射或乳房切除术后放疗的临界候选者,广泛LVI的发现可能对支持强化治疗起决定性作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Several data sets have demonstrated a correlation between lymphovascular invasion (LVI) and locoregional recurrence (LRR). Whether the observation of "extensive LVI" is a further and incremental determinant of LRR risk is unknown. We describe clinical outcomes in women with invasive breast cancer stratified by (1) absence of LVI (neg), (2) LVI focal or suspicious (FS-LVI), (3) usual (nonextensive) LVI (LVI), and (4) extensive LVI (E-LVI). METHODS AND MATERIALS: Between December 2009 and August 2021, 8837 patients with early-stage breast cancer were treated with curative intent and were evaluable. Clinical-pathologic details were abstracted by retrospective review. The description of LVI was abstracted from pathology reports. Recurrence and survival outcomes were compared based on the extent of LVI. A matched propensity score analysis compared outcomes between patients with LVI versus E-LVI. RESULTS: Of the 8837 patients studied, 5584 were negative, 461 had FS-LVI, 2315 had LVI, and 477 had E-LVI. Patients with E-LVI had an adverse risk profile compared with the other groups. The 5- and 10-year LRR cumulative incidence estimates in patients with E-LVI were 9.6% (95% CI, 7.1-13) and 13% (95% CI, 10-17), respectively, which were significantly higher than those observed in the usual LVI group (6.8% [5.7-7.9] and 10% [8.8-12], respectively). A statistically significant difference in LRR was demonstrated in univariable (HR, 1.4; 95% CI, 1.03-1.89; P = .029) and multivariable regression analysis (HR, 1.62; 95% CI, 1.15-2.27; P = .005) compared with nonextensive LVI. In an alternative approach, we performed a 2:1 propensity score matching analysis comparing patients with LVI to those with E-LVI. The hazard ratio for LRR (HR, 1.47; CI 1.02-2.14; P = .041) was suggestive of a higher risk associated with E-LVI. CONCLUSIONS: Our work suggests that patients with E-LVI are at a higher risk for LRR than those with usual LVI. For patients who are borderline candidates for regional nodal irradiation or post-mastectomy radiation therapy, the finding of E-LVI might be decisive in favor of intensified treatment.
引用
- Koleoso O, Toumbacaris N, Brogi E, et al. The Presence of Extensive Lymphovascular Invasion is Associated With Higher Risks of Local-Regional Recurrence Compared With Usual Lymphovascular Invasion in Curatively Treated Breast Cancer Patients. Int J Radiat Oncol Biol Phys. 2024. PMID: 38710417. doi:10.1016/j.ijrobp.2024.04.073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。